Phase 4 N=36 UW-CTRI Triple Medication Smoking Cessation Study
Smoking
Primary: Number of Participants With Adverse Events — 27; 26; 23; 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=70 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
Healthy
Primary: Efavirenz AUC0-inf (Single Dose) and AUC0-24(Multiple Dose) — 411.53; 620.36; 522.42; 183.97 h*uM
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Phase 4 N=14 Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
Heart Failure
Primary: Pulmonary Hypertension — 31.4; 29.1; 25.9; 25.4 mmHg
Phase 4 N=1,330 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants With Diphtheria and Tetanus Seroprotection — 100.0; 100.0; 99.8; 99.4 Percentage of participants
Phase 4 N=29 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Kidney Transplant · Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants
Phase 4 N=34 Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns
Depression
Primary: Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage — 469; 667; 706; 1002…
Phase 4 N=46 A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA)
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation (DC) of Study Drug — 4…
Phase 4 N=245 Does Dual Therapy Hasten Antidepressant Response?
Major Depressive Disorder
Primary: Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7 — 8; 9; 10 weeks…
Phase 4 N=296 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease
Primary: Percentage of 24-Hour Heartburn and Acid Regurgitation-Free Days in Non-Erosive Reflux Disease (NERD) Participants — 26.92 percentage of days
Phase 4 N=301 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 1.7; 0.4 Percentage of participants
Phase 4 N=59 A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Hepatitis C, Chronic
Primary: End of Treatment Response Rate at Week 72 in Genotype 1 — 68.2 Percentage of Participants
Phase 4 N=1,044 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
Hepatic Carcinoma
Primary: Incidence of Recurrence and Metastasis After Hepatectomy — 428; 155; 258; 161 Participants — p=0.0001
Phase 4 N=33 Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task — 8.6; 9.2 percent change in accuracy
Phase 4 N=29 Modafinil Effects on Cognition in Schizophrenia Patients
Schizophrenia
Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials